Intra-Cellular Therapies, Inc.

Sanofi is cementing its position as an immunology powerhouse by agreeing to acquire Blueprint Medicines Corp of the US and its soon-to-be blockbuster Ayvakit in a deal that could be worth up to $9.5bn

Biopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso

Johnson & Johnson is the first big pharma to report first quarter sales and earnings, and thus the first to outline expectations about the impact of tariffs on its financial outlook. So far, J&amp

Merger-and-acquisition activity in the biopharmaceutical sector had almost nowhere to go but up in the first quarter of 2025, following a historically low quarter in terms of total potential deal valu